Prellis’ proprietary 3-D bio-printing technology can produce large synthetic tissues and organoids used in pharmaceutical drug development and characterization.

Prellis is a pioneer in the construction of human cells, organoids and organoid systems based on proprietary biologics workflows. Prellis has developed the EXIS antibody discovery platform which can be used to generate antibody libraries with novel, target-specific drug candidates. The EXIS platform mimics the natural human immune process in vitro, representing the gold standard in drug discovery.